Allergan says it has been approached by another party
Actavis rumoured to be going head-to-head with rival Valeant for botox and eyecare group
Valeant to raise Allergan bid to at least $200 a share
Pharmaceutical firm’s offer values the Botox maker at $53bn
Valeant Pharmaceuticals continues to eye up Allergan
Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile
Tide turns for plant that once benefited from US job cuts
Scale of cuts savage despite a certain expectation of bad news
Allergan rejects Valeant Pharma’s ‘cut and slash’ takeover
Disappointed Valeant expected to raise cash and stock offer to drive through merger of companies with significant overlap of shareholders
Pfizer’s designs on AstraZeneca stir tax envy among rivals
Pitching by bankers on tax inversion targets has reached fever pitch
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices